Operator

Good day, and welcome to the top line results from Phase II IRIS study for ML-004 in Autism Spectrum Disorder. [Operator Instructions] Please note this call is being recorded. I would now like to turn the call over to Chris Kroeger, Co-Founder and Chief Executive Officer at MapLight Therapeutics. Please go ahead.

Christopher Kroeger
Founder, President, CEO & Director

Good morning, everyone, and welcome. I'm Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight Therapeutics. Thank you for joining us today. With me is Erin Foff, our Chief Medical Officer, who will be walking you through the Phase II data.

Before we begin, I'd like to remind you that today's webcast contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements represent management's judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from those expressed and/or implied by those statements. For more information on such risks and uncertainties, please refer to our filings with the Securities and Exchange Commission, which are available from the SEC or on our corporate website. Any forward-looking statements represent our views as of today, June 22, 2026. This presentation only speaks of the date hereof, and we don't undertake any duty